{"id":"W2908676058","doi":"10.1182/blood-2018-99-112069","title":"Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Brentuximab vedotin; Nivolumab; Medicine; CD30; Oncology; Internal medicine; Lymphoma; Population; Cancer research; Immunology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001083442,0.0007440094,0.0009529401,0.0001655991,0.0001770916,0.0008203721,0.0005169535,0.0005403275,0.002404997],"category_scores_gemma":[0.0005867567,0.0002091922,0.0009308817,0.0002032193,0.0003179313,0.0004669235,0.0002313185,0.001501945,0.0004399405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007590924,"about_ca_system_score_gemma":0.0006658124,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009253403,"about_ca_topic_score_gemma":0.00328547,"domain_scores_codex":[0.9997941,0.0001100693,0.000009412903,0.0000295361,0.0000199561,0.00003699438],"domain_scores_gemma":[0.9997019,0.00006929567,0.00005723595,0.00002003882,0.00002171137,0.0001298437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7303866,0.01966601,0.01176153,0.002486651,0.00391703,0.0002457451,0.0002468869,0.003818535,0.02952966,0.0003561093,0.008171321,0.1894139],"study_design_scores_gemma":[0.7227784,0.2249691,0.03560127,0.0002313548,0.002530716,0.0004246327,0.00009339728,0.002984879,0.003883625,0.0003878574,0.006075306,0.00003930501],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904812,0.005547915,0.0002402834,0.0003404913,0.0001036486,0.0005637713,0.0009573727,0.00008398915,0.001681387],"genre_scores_gemma":[0.9921085,0.002641724,0.0006431468,0.0005645167,0.0001244554,0.0005853889,0.001753948,0.00001974593,0.001558669],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002404997,"threshold_uncertainty_score":0.008045495,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01592534695735926,"score_gpt":0.2569216872865633,"score_spread":0.2409963403292041,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}